Cargando…

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection

Clear cell (cc) renal cell carcinoma (RCC) is the most common type of cancer found in the kidney accounting for ~90% of all kidney cancers. In 2012, there were ~337,000 new cases of RCC diagnosed worldwide with an estimated 143,000 deaths, with the highest incidence and mortality in Western countrie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Steven S, Quinn, David I, Dorff, Tanya B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045229/ https://www.ncbi.nlm.nih.gov/pubmed/27713636 http://dx.doi.org/10.2147/OTT.S97397

Ejemplares similares

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician
por: Storbjerg, Bent, et al.
Publicado: (2018)

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
por: Roof, Logan, et al.
Publicado: (2023)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
por: Lacy, Steven, et al.
Publicado: (2018)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety
por: Merle, Philippe, et al.
Publicado: (2022)

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review
por: Vashistha, Vishal, et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
por: Trojan, Jörg
Publicado: (2020)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
por: Deng, Shanshan, et al.
Publicado: (2021)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
por: Nakaigawa, Noboru, et al.
Publicado: (2023)

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
por: El-Khoueiry, Anthony B., et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
por: Sazuka, Tomokazu, et al.
Publicado: (2023)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
por: Coquan, Elodie, et al.
Publicado: (2021)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2019)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
por: Nakagawa, Takashi, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gbe1j5856h8u374dgnc5t265kn